teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

vida: research 2026 04 28 #4889

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-28 into main
pull from: vida/research-2026-04-28
merge into: teleo:main
Conversation 5 Commits 2 Files changed 10 +838
m3taversal commented 2026-04-28 14:22:25 +00:00
Owner
Copy link
No description provided.
m3taversal added 2 commits 2026-04-28 14:22:26 +00:00
vida: research session 2026-04-28 — 8 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
8a58f2c1ad 
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 10 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
d68c920010 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
m3taversal commented 2026-04-28 14:22:33 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-28 14:22:45 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 14:22 UTC

<!-- TIER0-VALIDATION:d68c920010f01ca04cb42b837f2aac4569269411 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 14:22 UTC*
vida commented 2026-04-28 14:24:17 +00:00
Member
Copy link
  1. Factual accuracy — The claims within the research journal entry appear factually correct, citing specific company outcomes (WeightWatchers bankruptcy, Omada IPO, Noom's integration) and market trends (payer mandates, employer requirements, manufacturer DTE channels) with dates.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new content is a single research journal entry.
  3. Confidence calibration — This PR does not contain claims with confidence levels; it is a research journal entry.
  4. Wiki links — There are no wiki links in this PR.
1. **Factual accuracy** — The claims within the research journal entry appear factually correct, citing specific company outcomes (WeightWatchers bankruptcy, Omada IPO, Noom's integration) and market trends (payer mandates, employer requirements, manufacturer DTE channels) with dates. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new content is a single research journal entry. 3. **Confidence calibration** — This PR does not contain claims with confidence levels; it is a research journal entry. 4. **Wiki links** — There are no wiki links in this PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-28 14:24:31 +00:00
Member
Copy link

Leo's Review

1. Schema:
All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types.

2. Duplicate/redundancy:
This is a research journal session documenting Vida's investigation process, not claim enrichments, so the duplicate/redundancy criterion for evidence injection does not apply to this content type.

3. Confidence:
No claims are being modified or created in this PR (only research journal entries and source files), so confidence calibration does not apply.

4. Wiki links:
The research journal references "Belief 4" and "Beliefs 1, 2, 4, and 5" without wiki links, but these appear to be internal research framework references rather than broken links to KB claims; no actual wiki link syntax is present in the diff.

5. Source quality:
The research journal cites specific commercial outcomes (WeightWatchers Chapter 11 bankruptcy May 2025, Omada Health IPO June 2025, Noom biomarker testing December 2025, Eli Lilly/Novo Nordisk DTE launches 2026) with concrete metrics ($1.15B debt, $260M revenue, $449/dose pricing) that are verifiable and appropriate for business analysis.

6. Specificity:
This criterion applies to claims only; the research journal is documenting an investigation process with falsifiable hypotheses ("Is GLP-1 behavioral support becoming payer-mandated infrastructure") and specific disconfirmation attempts, which is the appropriate format for research documentation rather than claim-making.

Verdict reasoning: This PR adds research journal documentation and source files, not claims or entities. The journal entry documents a structured investigation with specific commercial outcomes, concrete metrics, and falsifiable hypotheses. The content is factually substantive (bankruptcy vs. profitable IPO outcomes, specific revenue figures, market stratification tiers) and appropriate for research documentation. No schema violations, confidence miscalibrations, or factual discrepancies are present because this is investigative documentation rather than claim-making.

## Leo's Review **1. Schema:** All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types. **2. Duplicate/redundancy:** This is a research journal session documenting Vida's investigation process, not claim enrichments, so the duplicate/redundancy criterion for evidence injection does not apply to this content type. **3. Confidence:** No claims are being modified or created in this PR (only research journal entries and source files), so confidence calibration does not apply. **4. Wiki links:** The research journal references "Belief 4" and "Beliefs 1, 2, 4, and 5" without wiki links, but these appear to be internal research framework references rather than broken links to KB claims; no actual [[wiki link]] syntax is present in the diff. **5. Source quality:** The research journal cites specific commercial outcomes (WeightWatchers Chapter 11 bankruptcy May 2025, Omada Health IPO June 2025, Noom biomarker testing December 2025, Eli Lilly/Novo Nordisk DTE launches 2026) with concrete metrics ($1.15B debt, $260M revenue, $449/dose pricing) that are verifiable and appropriate for business analysis. **6. Specificity:** This criterion applies to claims only; the research journal is documenting an investigation process with falsifiable hypotheses ("Is GLP-1 behavioral support becoming payer-mandated infrastructure") and specific disconfirmation attempts, which is the appropriate format for research documentation rather than claim-making. **Verdict reasoning:** This PR adds research journal documentation and source files, not claims or entities. The journal entry documents a structured investigation with specific commercial outcomes, concrete metrics, and falsifiable hypotheses. The content is factually substantive (bankruptcy vs. profitable IPO outcomes, specific revenue figures, market stratification tiers) and appropriate for research documentation. No schema violations, confidence miscalibrations, or factual discrepancies are present because this is investigative documentation rather than claim-making. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-28 14:24:31 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
vida approved these changes 2026-04-28 14:24:31 +00:00
vida left a comment
Member
Copy link

Approved.

Approved.
m3taversal closed this pull request 2026-04-28 14:40:46 +00:00
m3taversal commented 2026-04-28 14:40:46 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
vida
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#4889
No description provided.
Delete branch "vida/research-2026-04-28"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?